- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00090311
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Children & Adolescents With Bipolar I Mania (ANCHOR 149)
January 3, 2013 updated by: AstraZeneca
A 3-wk, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Phase 3b Study of the Efficacy & Safety of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in the Treatment of Children & Adolescents With Bipolar I Mania (Abbreviated)
The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of children and adolescent patients with Bipolar I mania.
Study Overview
Study Type
Interventional
Enrollment (Actual)
220
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States
- Research Site
-
-
California
-
Riverside, California, United States
- Research Site
-
Sacramento, California, United States
- Research Site
-
San Diego, California, United States
- Research Site
-
-
Colorado
-
Denver, Colorado, United States
- Research Site
-
-
Florida
-
Alamonte, Florida, United States
- Research Site
-
Jacksonville, Florida, United States
- Research Site
-
Miami, Florida, United States
- Research Site
-
-
Georgia
-
Augusta, Georgia, United States
- Research Site
-
-
Illinois
-
Chicago, Illinois, United States
- Research Site
-
-
Kansas
-
Wichita, Kansas, United States
- Research Site
-
-
Louisiana
-
New Orleans, Louisiana, United States
- Research Site
-
-
Missouri
-
St. Charles, Missouri, United States
- Research Site
-
-
Nevada
-
Las Vegas, Nevada, United States
- Research Site
-
-
New Jersey
-
Clementon, New Jersey, United States
- Research Site
-
Piscataway, New Jersey, United States
- Research Site
-
-
New York
-
Rochester, New York, United States
- Research Site
-
-
North Carolina
-
Chapel Hill, North Carolina, United States
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, United States
- Research Site
-
Cleveland, Ohio, United States
- Research Site
-
Lyndhurst, Ohio, United States
- Research Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
- Research Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
- Research Site
-
-
Tennessee
-
Madison, Tennessee, United States
- Research Site
-
-
Texas
-
Austin, Texas, United States
- Research Site
-
Houston, Texas, United States
- Research Site
-
San Antonio, Texas, United States
- Research Site
-
-
Virginia
-
Richmond, Virginia, United States
- Research Site
-
Virginia Beach, Virginia, United States
- Research Site
-
-
Washington
-
Bellevue, Washington, United States
- Research Site
-
Kirkland, Washington, United States
- Research Site
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States
- Research Site
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient is able to provide written assent and the parents or legal guardian of the patient is able to provide written informed consent before beginning and study related procedures
- Patient has a documented clinical diagnosis of Bipolar I mania
- Patient's parent or legal guardian will be able to accompany the patient at each scheduled study visit
Exclusion Criteria:
- Patients (female) must not be pregnant or lactating
- Patients with a known intolerance or lack of response to previous treatment with quetiapine
- Patients who have previously participated in this study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Compare efficacy of Quetiapine with placebo in the treatment of bipolar I mania as assessed by the YMRS total score, change from baseline to Day 21
|
Secondary Outcome Measures
Outcome Measure |
---|
Compare the effect of Quetiapine with placebo in change from baseline to Day 21 percentage of patients with response, defined as a ≤ 12, evaluate safety and tolerability
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2004
Study Completion (Actual)
July 1, 2006
Study Registration Dates
First Submitted
August 25, 2004
First Submitted That Met QC Criteria
August 27, 2004
First Posted (Estimate)
August 30, 2004
Study Record Updates
Last Update Posted (Estimate)
January 4, 2013
Last Update Submitted That Met QC Criteria
January 3, 2013
Last Verified
January 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- D1441C00149
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Mayo ClinicCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Joshua RosenblatRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II DisorderCanada
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoNot yet recruitingBipolar Disorder | Bipolar Depression | Treatment- Resistant Bipolar Disorder | Type 2 Bipolar DisorderCanada
Clinical Trials on quetiapine fumarate
-
Norwegian University of Science and TechnologySt. Olavs Hospital; Alesund Hospital; Namsos Hospital; Volvat Medisinsk Senter...Recruiting
-
AstraZenecaCompletedSchizophreniaItaly, Germany, Austria, Spain, Denmark
-
AstraZenecaCompleted
-
AstraZenecaCompletedMajor Depressive DisorderUnited States
-
AstraZenecaTerminated
-
AstraZenecaCompletedSchizophrenia | Bipolar I DisorderUnited States, Russian Federation, Philippines, Malaysia, South Africa, Poland, Serbia, Ukraine, India
-
AstraZenecaCompletedSchizophreniaUnited States, Russian Federation, Philippines, Malaysia, South Africa, Germany, Poland, Serbia, India, Ukraine
-
AstraZenecaCompletedBipolar DisorderUnited States, Bulgaria, Peru, Russian Federation, Philippines, Malaysia, Lithuania, Romania, Ukraine, Argentina, Taiwan, Mexico, Thailand, India, Colombia
-
Torrent Pharmaceuticals LimitedCompleted